Flemming Ørnskov (born 1957/58) is a Danish businessman who has been the chief executive officer (CEO) of Shire plc, a FTSE 100 speciality biopharmaceutical company since 30 April 2013, succeeding Angus Russell.
He previously worked for Bayer.
Ørnskov received his MD from the University of Copenhagen, followed by an MBA from INSEAD, and a Master of Public Health (MPH) from Harvard University.